Abstract:Using UK Biobank data, we have shown synergistic inverse associations of obesity and diabetes with total prostate cancer risk, likely involving testosterone reduction for diabetes and oestrogen generation for obesity, which were attenuated in men with large waist size. Hip size and sex hormone binding globulin showed synergistic inverse associations with total prostate cancer risk. Background Obesity and diabetes are associated inversely with low‐grade prostate cancer risk and affect steroid hormone synthesis but whether they modify each other's impact on prostate cancer risk remains unknown. Methods We examined the independent associations of diabetes, body mass index (BMI), 'a body shape index' (ABSI), hip index (HI), circulating testosterone, sex hormone binding globulin (SHBG) (per one standard deviation increase) and oestradiol ≥175 pmol/L with total prostate cancer risk using multivariable Cox proportional hazards models for UK Biobank men. We evaluated multiplicative interactions (pMI) and additive interactions (relative excess risk from interaction (pRERI), attributable proportion (pAR), synergy index (pSI)) with obese (BMI ≥30 kg/m2) and diabetes. Results During a mean follow‐up of 10.3 years, 9417 incident prostate cancers were diagnosed in 195,813 men. Diabetes and BMI were associated more strongly inversely with prostate cancer risk when occurring together (pMI = 0.0003, pRERI = 0.032, pAP = 0.020, pSI = 0.002). ABSI was associated positively in obese men (HR = 1.081; 95% CI = 1.030–1.135) and men with diabetes (HR = 1.114; 95% CI = 1.021–1.216). The inverse associations with obesity and diabetes were attenuated for high‐ABSI ≥79.8 (pMI = 0.022, pRERI = 0.008, pAP = 0.005, pSI <0.0001 obesity; pMI = 0.017, pRERI = 0.047, pAP = 0.025, pSI = 0.0005 diabetes). HI was associated inversely in men overall (HR = 0.967; 95% CI = 0.947–0.988). Free testosterone (FT) was associated most strongly positively in normal weight men (HR = 1.098; 95% CI = 1.045–1.153) and men with diabetes (HR = 1.189; 95% CI = 1.081–1.308). Oestradiol was associated inversely in obese men (HR = 0.805; 95% CI = 0.682–0.951). The inverse association with obesity was stronger for high‐FT ≥243 pmol/L (pRERI = 0.040, pAP = 0.031, pSI = 0.002) and high‐oestradiol (pRERI = 0.030, pAP = 0.012, pSI <0.0001). The inverse association with diabetes was attenuated for high‐FT (pMI = 0.008, pRERI = 0.015, pAP = 0.009, pSI = 0.0006). SHBG was associated inversely in men overall (HR = 0.918; 95% CI = 0.895–0.941), more strongly for high‐HI ≥49.1 (pMI = 0.024). Conclusions Obesity and diabetes showed synergistic inverse associations with prostate cancer risk, likely involving testosterone reduction for diabetes and oestrogen generation for obesity, which were attenuated for high‐ABSI. HI and SHBG showed synergistic inverse associations with prostate cancer risk.

Obesity, Endogenous Hormone Metabolism, and Prostate Cancer Risk: A Conundrum of “Highs” and “Lows”

Interactions of obesity, body shape, diabetes and sex steroids with respect to prostate cancer risk in the UK Biobank cohort

Obesity Affects the Biopsy-Mediated Detection of Prostate Cancer, Particularly High-Grade Prostate Cancer: a Dose-Response Meta-Analysis of 29,464 Patients.

The Association Between Metabolic Abnormality and Endometrial Cancer: a Large Case-Control Study in China.

Glucose impairments and insulin resistance in prostate cancer: the role of obesity, nutrition and exercise

Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose–response meta-analysis of 36,927 patients

Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study

The Association Between Metabolic Status and Risk of Cancer Among Patients With Obesity: Metabolically Healthy Obesity vs. Metabolically Unhealthy Obesity

The impact of obesity and sexual behavior on prostate cancer risk is mediated by testosterone levels: a mendelian randomization study and mediation analysis

Do Obesity-Related Traits Affect Prostate Cancer Risk through Serum Testosterone? A Mendelian Randomization Study

Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions

Molecular interactions of leptin and prostate cancer

Obesity, Fat Distribution and Risk of Cancer in Women and Men: A Mendelian Randomisation Study

Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence

Adipose Tissues Have Been Overlooked as Players in Prostate Cancer Progression

Associations of body composition measures with circulating insulin-like growth factor-I, testosterone, and sex hormone-binding globulin concentrations in 16,000 men

Metabolic syndrome, obesity and cancer risk

Mechanistic Insights into the Link between Obesity and Prostate Cancer

Obesity and Cancer Risk: Recent Review and Evidence

Obesity and cancer risk: Emerging biological mechanisms and perspectives

Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms